Pharmacologic options for CNS infections caused by resistant Gram-positive organisms

References

• Kourbeti IS, Jacobs AV, Koslow M et al. Risk factors associated with post craniectomy meningitis. Neurosurgery60(2), 317–325 (2007).
   PubMed Web of Science ®Google Scholar
• Schlesinger LS, Ross SC, Schaberg DR. Staphylococcus aureus meningitis: a broad-based epidemiologic study. Medicine (Baltimore)66(2), 148–56 (1987).
   PubMed Web of Science ®Google Scholar
• Mollman HD, Haines SJ. Risk factors for postoperative neurosurgical wound infection: a case–control study. J. Neurosurg.64, 902–906 (1986).
   PubMed Web of Science ®Google Scholar
• McClelland S III , Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin. Infect. Dis.45, 55–59 (2007).
   PubMed Web of Science ®Google Scholar
• Korinek AM, Golmard JL, Elcheick A et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4,578 patients. Br. J. Neurosurg.19, 155–162 (2005).
   PubMed Web of Science ®Google Scholar
• Malis LI. Prevention of neurosurgical infection by intraoperative antibiotics. Neurosurgery5(3), 339–343 (1979).
   PubMed Web of Science ®Google Scholar
• NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control.31(8), 481–498 (2003).
   PubMed Web of Science ®Google Scholar
• Smith RW, Alksne JF. Infections complicating the use of external ventriculostomy. J. Neurosurgery44, 567–570 (1976).
   PubMed Web of Science ®Google Scholar
• Lozier AP, Sciacca RR, Romagnoli MF et al. Ventriculostomy related infections: a critical review of the literature. Neurosurgery51, 170–182 (2002).
   PubMed Web of Science ®Google Scholar
• Mayhall CG, Archer NH, Lamb VA et al. Ventriculostomy related infections: a prospective epidemiologic study. N. Engl. J. Med.310, 553–559 (1984).
   PubMed Web of Science ®Google Scholar
• Winfield JA, Rosenthal P, Kanter RK, Casella G. Duration of intracranial pressure monitoring does not predict daily risk of infectious complications. Neurosurgery33, 424–430 (1993).
   PubMed Web of Science ®Google Scholar
• Bader MK, Littlejohns L, Palmer S. Ventriculostomy and intracranial pressure monitoring: in search of a 0% infection rate. Heart Lung.24, 166–172 (1995).
   PubMed Web of Science ®Google Scholar
• Holloway KL, Barnes T, Choi S et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J. Neurosurg.85, 419–424 (1996).
   PubMed Web of Science ®Google Scholar
• Prabhu VC, Kaufman HH, Voelker JL et al. Prophylactic antibiotics with intracranial pressure monitors and external ventricular drains: a review of the evidence. Surg. Neurol.52, 226–236 (1999).
   PubMedGoogle Scholar
• Arabi Y, Memish ZA, Balkhy HH et al. Ventriculostomy-associated infections: incidence and risk factors. Am. J. Infect. Control33, 137–143 (2005).
   PubMed Web of Science ®Google Scholar
• Rebuck JA, Murry KR, Rhoney DH et al. Infection related to intracranial pressure monitors in adults: analysis of risk factors and antibiotic prophylaxis. J. Neurol. Neurosurg. Psychiatr.69, 381–384 (2000).
   PubMed Web of Science ®Google Scholar
• Kulkarni AV, Drake JM, Lamberti-Pasculli M. Cerebrospinal fluid shunt infection: a prospective study of risk factors. J. Neurosurg.94(2), 195–201 (2001).
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Zaas A, Fuchs HE, Goerge TM, Kaye K, Sexton DJ. Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infection pathogens. Clin. Infect. Dis.36(7), 858–862 (2003).
   PubMed Web of Science ®Google Scholar
• Pople IK, Bayston R, Hayward RD. Infection of cerebrospinal fluid shunts in infants: a study of etiological factors. J. Neurosurg.77, 29 (1992).
   PubMed Web of Science ®Google Scholar
• Arunodaya GR. Infections in neurology and neurosurgery intensive care unit. Neurol. India49(Suppl. 1), S51–S59 (2001).
   PubMedGoogle Scholar
• Quagliarello VJ, Scheld WM. Drug therapy: treatment of bacterial meningitis. N. Engl. J. Med.336, 708–716 (1997).
   PubMed Web of Science ®Google Scholar
• Albanese J, Leone M, Bruguerolle B et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother.44, 1356–1358 (2000).
   PubMed Web of Science ®Google Scholar
• Pfausler B, Spiss H, Beer R et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J. Neurosurg.98, 1040–1044 (2003).
   PubMed Web of Science ®Google Scholar
• Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N. Engl. J. Med.327(12), 864–872 (1992).
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis.39(9), 1267–1284 (2004).
   PubMed Web of Science ®Google Scholar
• Gnanalingham KK, Elsaghier A, Kibbler C et al. The impact of methicillin-resistant Staphylococcus aureus in a neurosurgical unit: a growing problem. J. Neurosurg.98(1), 8–13 (2003).
   PubMed Web of Science ®Google Scholar
• Reichert MC, Medeiros EA, Ferraz FA. Hospital-acquired meningitis in patients undergoing craniotomy: incidence, evolution, and risk factors. Am. J. Infect. Control.30, 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Hermsen ED, Rotschafer JC. Central nervous system infections. In: Pharmacotherapy: A Physiologic Approach. DiPiro JT (Ed), McGraw-Hill, NY, USA 1923–1942 (2007).
   Google Scholar
• Smith TL, Nathan BR. Central nervous system infections in the immune-competent adult. Curr. Treat. Options Neurol.4, 323–332 (2002).
   PubMedGoogle Scholar
• Andes DR, Craig WA. Bacterial meningitis: pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect. Dis. Clin. North Am.13, 595–618 (1999).
   PubMed Web of Science ®Google Scholar
• Kearney BP. The penetration of anti-infectives into the central nervous system. Neurol. Clin.17, 883–900 (1999).
   PubMed Web of Science ®Google Scholar
• McCormick MH, Stark WM, Pittenger GE, Pittenger RC, McGuire JM. Vancomycin, a new antibiotic I, chemical and biologic properties. Antibiot. Annu.3, 606–611 (1955–1956).
   PubMedGoogle Scholar
• Ziegler DW, Wolfe RN, McGuire JM. Vancomycin, a new antibiotic II, in vitro antibacterial studies. Antibiot. Annu.3, 612–618 (1955–1956).
   PubMedGoogle Scholar
• Griffith RS, Peck FB. Vancomycin, a new antibiotic III, preliminary clinical and laboratory studies. Antibiot. Annu.3, 619–622 (1955–1956).
   PubMedGoogle Scholar
• Anderson RC, Worth HM, Harris PN, Chen KK. Vancomycin, a new antibiotic IV, pharmacologic and toxicologic studies. Antibiot. Annu.4, 75–81 (1956–1957).
   Google Scholar
• Lee C, Anderson RC, Chen KK. Vancomycin, a new antibiotic V, distribution, excretion, and renal clearance. Antibiot. Annu.4, 82–89 (1956–1957).
   Google Scholar
• Higgins HM, Harrison WH, Wild GM, Bungay HR, McCormick MH. Vancomycin, a new antibiotic VI, purification and properties of vancomycin. Antibiot. Annu.5, 906–914 (1957–1958).
   PubMedGoogle Scholar
• Gump DW. Vancomycin for the treatment of bacterial meningitis. Rev. Infect. Dis.3(Suppl.), S289–S292 (1983).
   Google Scholar
• Hawley HD. Vancomycin therapy of bacterial meningitis. Am. J. Dis. Child.126, 261–264 (1960).
   Google Scholar
• Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Täuber MG. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis.58, 163–170 (2007).
   PubMedGoogle Scholar
• Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus – an antibiotic enters obsolescence. Clin. Infect. Dis.44, 1543–1548 (2007).
   PubMed Web of Science ®Google Scholar
• Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.44, 1536–1542 (2007).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Cui L, Kuroda. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol.9, 486–493 (2001).
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis.44, 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M-100-S16. PA, USA CLSI (2006).
   Google Scholar
• Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis.39, 539–545 (2004).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet.43(13), 925–942 (2004).
   PubMed Web of Science ®Google Scholar
• Drew R. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy27(2), 227–249 (2007).
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis.42(Suppl. 1), S35–S59 (2006).
   PubMed Web of Science ®Google Scholar
• Zyvox® (linezolid) package insert. Pfizer Pharmaceuticals. NY, USA (2007).
   Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother.42, 3251–3255 (1998).
   PubMed Web of Science ®Google Scholar
• Cook AM, Ramsey CN, Martin CA, Pittman T. Linezolid for the treatment of heteroresistant Staphylococcus aureus shunt infection. Pediatr. Neurosurg.41, 102–104 (2005).
   PubMedGoogle Scholar
• Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Tauber MG. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J. Antimicrob. Chemother.46, 981–985 (2000).
   PubMed Web of Science ®Google Scholar
• Shaikh ZHA, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand. J. Infect. Dis.34, 375–379 (2001).
   Google Scholar
• Villani P, Regazzi MR, Marubbi F et al. Cerebrospinal fluid linezolid concentrations in post-neurosurgical central nervous system infections. Antimicrob. Agents Chemother.46, 936–937 (2002).
   PubMed Web of Science ®Google Scholar
• Beer R, Engelhardt KW, Pfausler B et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob. Agents Chemother.51, 379–382 (2007).
   PubMed Web of Science ®Google Scholar
• Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection35, 271–274 (2007).
   PubMed Web of Science ®Google Scholar
• Pistella E, Campanile F, Bongiorno D et al. Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus endocarditis unresponsive to vancomycin therapy with linezolid. Scand. J. Infect. Dis.26, 222–225 (2004).
   Google Scholar
• Viale P, Pagani L, Cristini F et al. Linezolid for the treatment of central nervous system infections in neurosurgical infections. Scand. J. Infect. Dis.34, 456–459 (2002).
   PubMed Web of Science ®Google Scholar
• Amod F, Moodley I, Peer AK et al. Ventriculitis due to a hetero strain of vancomycin intermediate Staphylococcus aureus (hVISA): successful treatment with linezolid in combination with intraventricular vancomycin. J. Infect.50, 252–257 (2005).
   PubMed Web of Science ®Google Scholar
• Kruse AJ, Peerdeman SM, Bet PM, Debets-Ossenkopp YJ. Successful treatment with linezolid and rifampicin of meningitis due to methicillin-resistant Staphylococcus epidermitis refractory to vancomycin treatment. Eur. J. Clin. Microbiol. Infect. Dis.25, 135–137 (2006).
   PubMedGoogle Scholar
• Krueger WA, Kottler B, Will BE, Heininger A, Guggenberger H,Unertl KE. Treatment of meningitis due to methicillin-resistant Staphylococcus epidermitis with linezolid. J. Clin. Microbiol.42, 929–932 (2004).
   PubMed Web of Science ®Google Scholar
• Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative staphylococcus ventriculitis. Ann. Pharmacother.40, 1451–1455 (2006).
   PubMed Web of Science ®Google Scholar
• Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid. Eur. J. Clin. Microbiol. Infect. Dis.20, 432–434 (2001).
   PubMed Web of Science ®Google Scholar
• Silva PS, Monteiro Neto H, Sejas LM. Successful treatment of vancomycin-resistant enterococcus ventriculitis in a child. Braz. J. Infect. Dis.11, 297–299 (2007).
   PubMedGoogle Scholar
• Kanchanapoom T, Koirala J, Goodrich J, Agamah E, Khardori N. Treatment of central nervous system infection by vancomycin-resistant Enterococcus faecium. Diagn. Microbiol. Infect. Dis.45, 213–215 (2003).
   PubMed Web of Science ®Google Scholar
• Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr. Infect. Dis. J.21, 798–800 (2002).
   PubMed Web of Science ®Google Scholar
• Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin. Infect. Dis.33, 477–482 (2001).
   PubMed Web of Science ®Google Scholar
• Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit. Care Med.29(12), 2383–2385 (2001).
   PubMed Web of Science ®Google Scholar
• Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone plus linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin. Microbiol. Infect.12, 391–394 (2006).
   PubMed Web of Science ®Google Scholar
• Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Euro. J. Neurol.12, 536–542 (2005).
   PubMed Web of Science ®Google Scholar
• Vigano SM, Edefonti A, Ferraresso M et al. Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a pediatric renal transplant recipient. Pediatr. Nephrol.20, 1186–1188 (2005).
   PubMedGoogle Scholar
• Lewis KE, Ebden P, Wooster SL, Rees J, Harrison GA. Multi-system infection with Nocardia farcinica-therapy with linezolid and minocycline. J. Infect.46, 190–202 (2003).
   Google Scholar
• Moylett EH, Pacheco SE, Brown-Elliot BA et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin. Inefct. Dis.36, 313–318 (2003).
   PubMed Web of Science ®Google Scholar
• Salin F, Vianello F, Manara R et al. Linezolid in the treatment of brain abscess due to Peptostreptococcus. Scand. J. Infect. Dis.38, 203–205 (2006).
   PubMed Web of Science ®Google Scholar
• Sabbatani S, Manfredi R, Frank G, Chiodo F. Capnocytophaga spp. brain abscess in an immunocompetent host: problems in antimicrobial chemotherapy and literature review. J. Chemother.16, 497–501 (2004).
   Google Scholar
• Klibanov OM, Filicko JE, DeSimone JA Jr, Tice DS. Sensrineural hearing loss associated with intrathecal vancomycin. Ann. Pharmacother.37, 61–65 (2003).
   PubMed Web of Science ®Google Scholar
• Synercid® (quinupristin/dalfopristin) package insert. Monarch Pharmaceuticals, Bristol, TN, USA (2003).
   Google Scholar
• Bergeron M, Montay G. The pharmacokinetics of quinupristin/ dalfopristin in laboratory animals and in humans. J. Antimicrob. Chemother.39(Suppl. A), 129–138 (1997).
   PubMed Web of Science ®Google Scholar
• Tarasi A, Dever LL, Tomasz A. Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis. J. Antimicrob. Chemother.39(Suppl. A), 121–127 (1997).
   PubMedGoogle Scholar
• Trostdorf F, Reinert RR, Schmidt H et al. Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis. J. Antimicrob. Chemother.43, 87–94 (1999).
   PubMed Web of Science ®Google Scholar
• Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant and antibiotic cure. 1(1), 95–96 (1995).
   Google Scholar
• Gransden WR, King A, Marossy D et al. Quinupristin/dalfopristin in neonatal Enterococcus faecium meningitis. Arch. Dis. Child. Fetal Neonatal Ed.78, f235–f236 (1998).
   PubMed Web of Science ®Google Scholar
• Garey KW, Tesoro E, Muggia V et al. Cerebrospinal fluid concentrations of quinupristin/dalfopristin in patients with Enterococcus faecalis ventriculitis. Pharmacotherapy2, 748–750 (2001); Erratum in Pharmacotherapy2, P-8 (2001).
   Google Scholar
• Williamson JC, Glazier SS, Peacock JE. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin. Neurol. Neurosurg.104, 54–56 (2002).
   PubMed Web of Science ®Google Scholar
• Tush GM, Huneycutt S, Phillips A et al. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enteroccus faecium shunt infection. Clin. Infect. Dis.26, 1460–1461 (1998).
   PubMed Web of Science ®Google Scholar
• Tan TY, Pitman I, Penrose-Stevens A et al. Treatment of vancomycin-resistant Enteroccus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. J. Infect.41, 95–97 (2000).
   PubMed Web of Science ®Google Scholar
• Cubicin® (daptomycin) package insert. Cubist Pharmaceuticals, Lexington, MA, USA (2007).
   Google Scholar
• Schriever CA, Fernández C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm.62, 1145–1158 (2005).
   PubMedGoogle Scholar
• Cottagnoud P, Pfister M, Acosta F et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother.48, 3928–3933 (2004).
   PubMed Web of Science ®Google Scholar
• Cottagnoud P, Acosta F, Cottagnoud M et al. Daptomycin (D), alone or in combination with ceftriaxone (CRO) is highly efficacious against penicillin-resistant pneumococci in experimental meningitis. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA 27–30 September (2006). (Poster B-1126).
   Google Scholar
• Gerber P, Stucki A, Acosta F et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J. Antimicrob. Chemother.57, 720–723 (2006).
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Schurch C, Cottagnoud P et al. Prevention of brain injury by non bacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob. Agents Chemother.51(6), 2173–2178 (2007).
   PubMed Web of Science ®Google Scholar
• Stucki A, Cottagnoud M, Winkelmann V, Schaffner T, Cottagnoud P. Daptomycin produced an enhanced bactericidal activity compared to ceftriaxone in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall measured by H-choline release in the CSF. Antimicrob. Agents Chemother.51(6), 2249–2252 (2007).
   PubMed Web of Science ®Google Scholar
• Atodaria S, Aipoalani D, Walker J et al. Daptomycin response in MRSA orbital cellulites and meningitis. Presented at: Proceedings from the American College of Physicians Annual Meeting. San Francisco, CA, USA 4–7 May (2005).
   Google Scholar
• Tygacil® (tigecycline) package insert. Wyeth Pharmaceuticals. PA, USA (2007).
   Google Scholar
• Zinner SH. Overview of antibiotic use and resistance: setting the stage for tigecycline. Clin. Infect. Dis.41, S289–S292 (2005).
   PubMedGoogle Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis.41, S303–S314 (2005).
   PubMed Web of Science ®Google Scholar
• Bradford PA, Weaver-Sands DT, Peterson PJ. In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials for treatment of complicated skin and skin-structure infections and complicated intra-abdominal infection. Clin. Infect. Dis.41, S315–S332 (2005).
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis.41, S333–S340 (2005).
   PubMed Web of Science ®Google Scholar
• Meagher Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics profile of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother.58, 256–265 (2006).
   PubMedGoogle Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother.58, 1221–1229 (2006).
   PubMed Web of Science ®Google Scholar
• Fang G, Weiss W, Scheld W. Comparative efficacy of GAR-963 (GAR), a novel glycylcycline, alone and in combination with vancomycin against highly penicillin-resistant Streptococcus pneumoniae. experimental meningitis in rabbits. Presented at: Program and abstracts of the Fortieth Interscience Conference on Antimicrobial agents and Chemotherapy. Toronto, Canada. (2000) (Abstract868).
   Google Scholar
• Fang Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert. Rev. Anti Infect. Ther.5(3) 393–401 (2007).
   PubMedGoogle Scholar
• Levine DP. Vancomycin: a history. Clin. Infect. Dis.42, S5–S12 (2006).
   PubMed Web of Science ®Google Scholar
• Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann. Pharmacother.41(2), 296–308 (2007).
   PubMed Web of Science ®Google Scholar
• May AK, Fleming SB, Carpenter RO et al. Influence of broad-spectrum antibiotic prophylaxis on intracranial pressure monitor infections and subsequent infectious complications in head-injured patients. Surg. Infect.5(7), 409–417 (2005).
   Google Scholar
• Guay D. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy24(1), 58–68 (2004).
   PubMed Web of Science ®Google Scholar
• Dorr MB, Jabes D, Cavaleri M et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother.55(S2), ii25–ii30 (2005).
   PubMed Web of Science ®Google Scholar
• Ceftobiprole Medocaril. Drugs R. D.7(5), 305–311 (2006).
   PubMedGoogle Scholar
• Bhavnani S, Owen J, Loutit J, Porter S, Ambrose P. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy subjects. Diagn. Microbiol. Infect. Dis.50(2), 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Glycopeptides in clinical development: pharmacologic profile and clinical perspectives. Curr. Opin. Pharmacol.4, 471–478 (2004).
   PubMed Web of Science ®Google Scholar
• Gerber J, Smirnov A, Wellmer A et al. Activity of LY333328 in experimental meningitis caused by a streptococcus pneumoniae strain susceptible to penicillin. Antimicrob. Agents Chemother.45, 2169–2172 (2001).
   PubMed Web of Science ®Google Scholar
• Bhavnani S, Passarell J, Owen J, Loutit J, Porter S, Ambrose P. Pharmacokinetic– pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.50, 994–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Cabellos C, Fernandez A, Maiques J et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother.47, 1907–11 (2003).
   PubMed Web of Science ®Google Scholar
• Higgins D, Chang R, Debabov D et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.49(3), 1127–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw J, Seroogy J, Kaniga K, Higgins D, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother.49(1), 195–201 (2005).
   PubMed Web of Science ®Google Scholar
• Stryjewski M, Chu V, O’Riordan W et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 Study. Antimicrob. Agents Chemother.50(3), 862–867 (2006).
   PubMed Web of Science ®Google Scholar
• Stucki A, Gerber P, Acosta F, Cottagnoud M, Cottagnoud P. Efficacy of telavancin against penicillin-resistant pneumococci and Staphyloccocus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob. Agents Chemother.50(2), 770–773 (2006).
   PubMed Web of Science ®Google Scholar
• Malabarba A, Goldstein B. Origin, structure and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother.55(S2), ii15–ii20 (2005).
   PubMed Web of Science ®Google Scholar
• Lin G, Credito K, Ednie L, Appelbaum P. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother.49(2), 770–772 (2005).
   PubMed Web of Science ®Google Scholar
• Pope S, Roecker A. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy26(7), 908–918 (2006).
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb A, Dorr M et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother.48(3), 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein BP, Seltzer E, Flamm RK, Sahm DF. Dalbavancin Phase three skin and skin structure studies: pathogens and microbiological efficacy. Presented at: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC , USA (2005) (Abstract L1577).
   Google Scholar
• Solon EG, Dowell JA, Lee J, King SP, Damle BD. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits. Antimicrob. Agents Chemother.51(8), 3008–3010 (2007).
   PubMed Web of Science ®Google Scholar
• Arias C, Singh K, Panesso D, Murray B. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase-producing and vancomycin-resistant isolates. Antimicrob. Agents Chemother.51(6), 2043–2047 (2007).
   PubMedGoogle Scholar
• Chambers H. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect.12(S2), 17–22 (2006).
   PubMed Web of Science ®Google Scholar
• Vandaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew D. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.49(9), 3789–3793 (2005).
   PubMedGoogle Scholar
• Noel G. Clinical profile of ceftobiprole, a novel β-lactam Antibiotic. Clin. Microbiol. Infect.13(Suppl. 2), 25–29 (2007).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Pypstra R. Ceftobiprole activity against baseline pathogens from a complicated skin and skin structure infection clinical trial. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA 27–30 September (2006) (Abstract E0116).
   Google Scholar
• Amsler KM, Bush K, Strauss R. Bajaksouzian S, Windau A, Heep M, Jacobs MR. Successful treatment of complicated skin infections (cSSSI) due to staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) with ceftobiprole. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA 27–30 September (2006) (Abstract L1212).
   Google Scholar
• Hawser S, Lociuro S, Islam K. Dihidrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol.71(7), 941–948 (2006).
   PubMed Web of Science ®Google Scholar
• Kohlhoff SA, Roblin P, Reznik T, Haswer S, Islam K, Hammerschlag MR. In vitro activity of a novel diaminopyrimidine compound, Iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob. Agents Chemother.48(5), 1885–1886 (2004).
   PubMed Web of Science ®Google Scholar